Overview
Rapid Antibody Production
Gram-scale Antibody Production
Antibody+X
Catalog Antibody Products
As antibody-based therapeutics continue to diversify, their levels of development maturity vary – while formats such as bispecific antibodies and ADCs have received market approval, others like antibody-radionuclide and antibody-nucleic acid conjugates remain in early-stage and require further research to validate their pharmaceutical feasibility and commercial potential.
To meet these evolving demands, Sanyou Bio offers its Antibody + X customized development service, supporting the R&D of complex formats including antibody-small molecule conjugates, antibody-protein fusions, multispecific antibodies, and antibody-nucleic acid complexes. This platform delivers flexible and innovative solutions for next-generation biotherapeutics.
Note: The workflow outlined above also applies to antibody–small molecule conjugates. For antibody–protein combinations, both conjugation and fusion expression strategies are available. Antibody–antibody constructs are typically developed through fusion expression to ensure stability and expression efficiency
As antibody-based therapeutics continue to diversify, their levels of development maturity vary – while formats such as bispecific antibodies and ADCs have received market approval, others like antibody-radionuclide and antibody-nucleic acid conjugates remain in early-stage and require further research to validate their pharmaceutical feasibility and commercial potential.
To meet these evolving demands, Sanyou Bio offers its Antibody + X customized development service, supporting the R&D of complex formats including antibody-small molecule conjugates, antibody-protein fusions, multispecific antibodies, and antibody-nucleic acid complexes. This platform delivers flexible and innovative solutions for next-generation biotherapeutics.
Note: The workflow outlined above also applies to antibody–small molecule conjugates. For antibody–protein combinations, both conjugation and fusion expression strategies are available. Antibody–antibody constructs are typically developed through fusion expression to ensure stability and expression efficiency
Overview
Rapid Antibody Production
Gram-scale Antibody Production
Antibody+X
Catalog Antibody Products
As antibody-based therapeutics continue to diversify, their levels of development maturity vary – while formats such as bispecific antibodies and ADCs have received market approval, others like antibody-radionuclide and antibody-nucleic acid conjugates remain in early-stage and require further research to validate their pharmaceutical feasibility and commercial potential.
To meet these evolving demands, Sanyou Bio offers its Antibody + X customized development service, supporting the R&D of complex formats including antibody-small molecule conjugates, antibody-protein fusions, multispecific antibodies, and antibody-nucleic acid complexes. This platform delivers flexible and innovative solutions for next-generation biotherapeutics.
Note: The workflow outlined above also applies to antibody–small molecule conjugates. For antibody–protein combinations, both conjugation and fusion expression strategies are available. Antibody–antibody constructs are typically developed through fusion expression to ensure stability and expression efficiency
As antibody-based therapeutics continue to diversify, their levels of development maturity vary – while formats such as bispecific antibodies and ADCs have received market approval, others like antibody-radionuclide and antibody-nucleic acid conjugates remain in early-stage and require further research to validate their pharmaceutical feasibility and commercial potential.
To meet these evolving demands, Sanyou Bio offers its Antibody + X customized development service, supporting the R&D of complex formats including antibody-small molecule conjugates, antibody-protein fusions, multispecific antibodies, and antibody-nucleic acid complexes. This platform delivers flexible and innovative solutions for next-generation biotherapeutics.
Note: The workflow outlined above also applies to antibody–small molecule conjugates. For antibody–protein combinations, both conjugation and fusion expression strategies are available. Antibody–antibody constructs are typically developed through fusion expression to ensure stability and expression efficiency
+86 21 3368 1627
protein@sanyoubio.com
abx.sanyoubio.com.cn
